Males and females differ in their biochemistry. Often these differences are not considered in early stage and pre-clinical research leading to a biased understanding of human health (e.g. see Nature, Neuroscience & Biobehavioral Reviews and Gendered Innovations). The LIBRA project therefore not only aims to address equality in the work place, but also in the research content.
The issue of including sex and gender considerations in pre-clinical experimental design impacts not only on academics, but also has strategic and financial implications for the pharmaceutical industry as well as research funding organisations. Therefore to catalyse change, LIBRA are organising a workshop at the Babraham Institute in Cambridge, UK on Sex & Gender in Research & Experimental Design. This will bring funders, industry, publishers and other stakeholders from across Europe together to discuss the challenges and opportunities around this issue with the aim of inspiring participants to carry out and promote better science through the consideration of sex and gender.
The programme can be downloaded at the bottom of this page.
Sabine Oertelt-Prigione, Professor of Gender in Primary and Transmural Care, Radboud University, Nijmegen
Natasha Karp, Senior Research Statistician, AstraZeneca, Cambridge
Jim Smith, Director of Science, Wellcome Trust, London
Peter Brown, Director of the Irish Research Council, Dublin
Irene Miguel-Aliaga, Professor, Imperial College, London
Stephane Berghmans, Vice president of Academic Relations EU at Elsevier
Pavel Ovseiko, Senior Research Fellow in Health Policy and Management, University of Oxford
Wilbert Zwart, Group Leader, NKI, Amsterdam
Cheryl Smythe, Chair of Babraham Institute’s Equality & Diversity team and LIBRA consortium member
Additional confirmed organisations are Cancer Research UK, ScienceEurope, Swiss National Science Foundation, German Research Foundation, Swedish Research Council, NC3Rs, AAAS Science International, Advance HE (Athena SWAN Charter), UK Home Office, Sanita Italian Funding Agency, Dutch Cancer Society (KWF), The Netherlands Organisation for Health Research and Development (ZonMw), Technology Agency of the Czech Republic, MedImmune, Biotechnological and Biological Sciences Research Council (BBSRC, UK), Medical Research Council (MRC, UK), Royal Society of Chemistry, Nature, CNRS, Science Foundation Ireland.